By Sherri Oslick --
Pharmaceuticals, Inc. et al. v. Fresenius Kabi USA, LLC
3:13-cv-00139; filed January 17, 2013 in the Southern District of California
Cadence Pharmaceuticals, Inc.; SCR Pharmatop
• Defendant: Fresenius Kabi USA, LLC
Infringement of U.S. Patent Nos. 6,028,222 ("Stable Liquid Paracetamol Compositions, and Method for Preparing the Same," issued February 22, 2000) and 6,992,218 ("Method for Obtaining Aqueous Formulations of Oxidation-Sensitive Active Principles," issued January 31, 2006), both licensed to Cadence, following a Paragraph IV certification as part of Fresenius' filing of an ANDA to manufacture a generic version of Cadence's Ofirmev® (acetaminophen injection, used for the management of mild to moderate pain, the management of moderate to severe pain with adjunctive opioid analgesics, and the reduction of fevers). View the complaint here.
Bioprojet SCR v. Kappos
1:13-cv-00055; filed January 14, 2013 in the Eastern District of Virginia
Review and correction of the patent term adjustment calculation made by the U.S. Patent and Trademark Office for U.S. Patent No. 8,222,294 ("Combinations of an Anti Emetic Agent and an Enkephalinase Inhibitor," issued July 17, 2012). View the complaint here.
Wyeth LLC et al. v. Kappos
1:13-cv-00049; filed January 10, 2013 in the Eastern District of Virginia
Wyeth LLC; Janssen Alzheimer Immunotherapy
• Defendant: Hon. David J. Kappos
Review and correction of the patent term adjustment calculation made by the U.S. Patent and Trademark Office for U.S. Patent No. 8,227,403 ("A-β Immunogenic Peptide Carrier Conjugates and Methods of Producing Same," issued July 24, 2012). View the complaint here.